CAB-LA PrEP for new mothers: safer HIV prevention for breastfeeding women in Botswana
Official title: Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
Funded at Beth Israel Deaconess Medical Center · NIH-11385295 · Data updated 2026-11-12
A study tests a long-acting HIV prevention injection for breastfeeding women who are at high risk of HIV in Botswana.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 24, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $252,304 |
| NIH project number | 5R01HD108047-05 |
| Project ID | NIH-11385295 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are high-risk, breastfeeding women in the postpartum period in settings similar to Botswana who are interested in long-acting PrEP.
✕Less likely to help
Women not at high risk or not comfortable with injectable PrEP may see little to no benefit.
What this research studies
This project focuses on delivering long-acting cabotegravir PrEP to high-risk women immediately after giving birth and pairing follow-up PrEP care with postpartum and pediatric services. Researchers will examine how well this injectable PrEP works in real-world postpartum settings and whether it is safe for breastfeeding mothers and their babies. The study aims to identify practical ways to reach young women who may have limited contact with health services and to streamline delivery of PrEP during the postpartum period. Outcomes will include safety in breastfeeding, adherence, and feasibility of integrating PrEP with maternity and child-health care.
Why it matters
Potential benefit: If successful, the approach could reduce new HIV infections among new mothers and prevent mother-to-child transmission by facilitating easier, safer PrEP during the postpartum period.
How similar studies have gone: Preliminary data suggest long-acting PrEP can reduce HIV infections compared with oral PrEP, but real-world postpartum implementation data are needed.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Zash, Rebecca Marie — Beth Israel Deaconess Medical Center
- Study coordinator: Zash, Rebecca Marie
Related research
Other NIH-funded projects on the same topics.
-
CAB-LA PrEP for breastfeeding women after delivery in Botswana
This study tests a long-acting HIV prevention shot for new mothers who are breastfeeding in Botswana to see if it prevents HIV safely and effectively.
-
Long-acting injectable HIV prevention for breastfeeding mothers
This project offers long-acting injectable cabotegravir to high-risk breastfeeding women starting at delivery, with follow-up through post-partum and baby-care clinics to prevent HIV.
-
Long-acting injectable HIV prevention for breastfeeding new mothers
This project looks at whether a long-acting injectable HIV prevention shot (cabotegravir) given after childbirth can safely protect breastfeeding women at high risk of HIV.
-
Exploring a new HIV prevention method for breastfeeding women in Botswana
This study is looking at a long-lasting injectable HIV prevention medication for breastfeeding women in Botswana to see if it’s safe and helps them stay protected from HIV while making it easier to get the care they need after having a baby.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.